Blog

Real-time drug tracking will become a viable option for clinical trials by the end of 2022, with end-to-end tracking of every step of the drug’s journey.

With master protocols, each site has to perform its own approval process in order to begin working under a new protocol version, resulting in multiple protocol versions being used at the same time. How can you manage this? Here are 3 simple steps.

A master protocol acts like a map showing many paths a clinical trial may take, where the sponsors don’t know in which direction their study will evolve, until the trial is under way.

Integrations don't need to involve complicated coding to develop. Modern tech can simplify implementation and enable a conversation between systems.

CSPs should be empowered with a good level of understanding what variables or information is critical to model supply planning (feasibility planning to study planning) so they can react and make decisions more effectively.

Over the life of a study, the amount of time and resources spent on changes to a system can significantly impact the study – but do they have to?

Did you know that Phase 1 trials can be even more complex than their Phase 2 and 3 counterparts? Don't let scale be the determining factor in choosing to leverage an RTSM. Here are 5 questions to ask when you consider an RTSM for your next Phase 1 study.

Having an IRT/RTSM for your IITs will help with supply chain management since IITs traditionally draw from the same pool of drugs as manufacturer-sponsored studies. See how.

Traditional RTSM / IWRS customer support models are no longer sufficient. Redefine the customer experience by using these 5 pillars of excellence.